Аллергический ринит и бронхиальная астма: двойной удар по дыхательной системе. Как добиться контроля

1. Аллергический ринит. Клинические рекомендации. РААКИ, НМАО, СПР, 2020 [Allergic rhinitis. Clinical guidelines. RAACI, NMAO, UPR, 2020 (in Russian)].
2. Jeffery PK, Godfrey RWA, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis. 1992;145:890-9.
3. Mandl M, et al. Ann Allergy Asthma Immunol. 1997;79:370-8.
4. Cutler DL, et al. Pediatr Asthma Allergy Immunol. 2006;19:145-53.
5. Haughney J, et al. Respir Med. 2008;102:1681-93.
6. Boulet LP. et al. Chest. 2006;129:661-8.
7. Chalmers GW, et al. Chest. 2001;120:1917-22.
8. Fauler J, et al. Eur J Clin Invest. 1997;27:43-7.
9. Dixon AE. Proc Am Thorac Soc. 2010;7:325-35. 
10. Pratley RE, et al. Obes Res. 1995;3:563-71.
11. Ferrante AW Jr. J Intern Med. 2007;262:408-14. 
12. Shore SA, et al. J Allergy Clin Immunol. 2005;115:103-9. 
13. Shore SA, et al. J Allergy Clin Immunol. 2006;118:389-95.
14. Pinar E, Eryigit O, Oncel S, et al. Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis. Auris Nasus Larynx. 2008;35(1):61-6. DOI:10.1016/j.anl.2007.06.004
15. Berkowitz R, Roberson S, Zora J, et al. Mometasone Furoate Nasal Spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc. 1999;20(3):167-72.
16. Mosges R, Bachert C, Rudack C, et al. Efficacy and safety of Mometasone furoate nasal spray in the treatment of chronic rhinosinusitis. Adv Ther. 2001;28(3):238-49. DOI:10.1007/s12325-010-0105-7
17. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116(6):1289-95. DOI:10.1016/j.jaci.2005.08.044
18. Niti Sardana, et al. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy Asthma Proc. 2010;31:5-9. DOI:10.2500/aap.2010.31.3308
19. HealthStar Communications Inc, in partnership with Schulman Ronca and Bucuvalas Inc. Allergies in America: a landmark survey of nasal allergy sufferers. Executive summary. Florham Park, NJ: Altana Pharma US Inc, 2006.
20. Meltzer E, Blaiss M, Derebery M, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol. 2009;124:43-70. 
21. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758-64.
22. Asher M, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-43.
23. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004;59:1205-10.
24. Lombardi C, Gani F, Landi M, et al. Quantitative assessment of the adherence to sublingual Immunotherapy. J Allergy Clin Immunol. 2004;113:1219-20.
25. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol. 2006;117:946-8.
26. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Otolaryngol Head Neck Surg. 2007;136(Suppl. 6):S107-24. 
27. Köberlein J, Kothe A, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:192-9. 
28. Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med. 2006;100(2):354-62.
29. Bender BG. Motivating patient adherence to allergic rhinitis treatments. Curr Allergy Asthma Rep. 2015;15(3):10. DOI:10.1007/s11882-014-0507-8
30. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol. 2002;88(4):391-4. DOI:10.1016/S1081-1206(10)62370-8
31. Smits W, Inglefield JT, Letz K, et al. Improve immunotherapy with a rapid allergen vaccination schedule: A study of 137 patients. Ear Nose Throat J. 2003;82:881-7.
32. Adamia N, Jorjoliani L, Manjavidze N, et al. Psycho-emotional characteristics of the adolescents with allerrgic rhinitis. Georgian Med News. 2015;243:38-42.
33. He X, Feng Y, Dong YY, et al. Allergic rhinitis and psychological state assessment. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31(5):400-3 (in Chinese).
34. Леббех И. Особенности коммуникации врачебного приема. Цикл «Доктор. Как разговаривать с пациентом и влиять на его приверженность». Издательские решения по лицензии Ridero, 2020 [Lebbekh I. Features of the communication of a medical appointment. Cycle “Doctor. How to talk to a patient and influence his adherence“. Publishing solutions licensed Ridero, 2020 (in Russian)]. 
35. Emanuel TJ, Emanuel LL. Four Models of the Physician-Patient Relationship. JAMA. 1992;267(16):2221-6.
36. Ледванова Т.Ю., Лим В.Г., Свистунов А.А., и др. Коммуникативная компетентность врача как часть компетентностной модели подготовки специалиста. Менеджмент качества и инновации в образовании: региональный аспект. В 2 т. М.: РГТЭУ, 2010 [Ledvanova TYu, Lim VG, Svistunov AA, et al. Communicative competence of a doctor as part of the competence model of training a specialist. Quality management and innovation in education: regional aspect. In 2 vol. Moscow, 2010 (in Russian)]. 
37. Андриянова Е.А., Носкова С.В. Компетентностная модель выпускника медицинского вуза. Педагогические технологии реализации компетентностного подхода в современном медицинском образовании. Сборник статей межрегион. науч.-практич. конф. Саратов: СГМУ, 2009 [Andriianova EA, Noskova SV. Competence model of a medical university graduate. Pedagogical technologies for the implementation of the competence-based approach in modern medical education. Collection of articles interregion. Scientific-practical conf. Saratov: SSMU, 2009 (in Russian)]. 
38. Татур Ю.Г. Компетентность в структуре модели качества подготовки специалиста. Высшее образование сегодня. 2004;3:20-6 [Tatur IuG. Kompetentnost' v strukture modeli kachestva podgotovki spetsialista. Vysshee obrazovanie segodnia. 2004;3:20-6 (in Russian)]. 
39. Ha JF, Longnecker N. Doctor-patient communication: a review. Ochsner J. 2010;10(1):38-43.
40. Kafetsios K, Anagnostopoulos F, Lempesis E, Valindra A. Doctors’ Emotion Regulation and Patient Satisfaction: A Social-Functional Perspective. Health Commun. 2014;29(2):205-14. DOI:10.1080/10410236.2012.73815 
41. Pirumyan T, Davtyan S. Tolerance as a constructive mechanism of dialogue in the field of Healthcare. Wisdom. 2016;7(2). DOI:10.24234/wisdom.v2i7.136
42. Aruguete MS, Roberts CA. Gender, Affiliation, and Control in Physician–Patient Encounters. Sex Roles. 2000;42:107-18.
43. Deontological Guidelines. Available at: http://www.ceom-ecmo.eu/en/deontological-guidelines-144. Accessed: 02.08.2021.
44. Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat Med. 2012;18(5):726-35. DOI:10.1038/nm.2768
45. Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75(12):3069-76. DOI:10.1111/all.14586
46. Roth-Walter F, Adcock IM, Benito-Villalvilla C, et al. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. Allergy. 2019;74(3):432-48. DOI:10.1111/all.13642
47. Theron AJ, Steel HC, Tintinger GR, et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. Immunol Res. 2014;2014:608930.
48. Cottini M, et al. Asthma phenotypes: the intriguing selective intervention with Montelukast. Asthma Res Pract. 2016;2:11.
49. Kim CK, Callaway Z, Park JS, et al. Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma. Allergy Asthma Immunol Res. 2018;10(6):686-97.
50. Okubo K, Kurono Y, Ichimura K, et al; Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020;69(3):331-45. DOI:10.1016/j.alit.2020.04.001
51. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. 2018.
52. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108-352.
53. Urdaneta E, Tunceli K, Gates D. Effect of mometasone furoate nasal spray on moderate-to-severe nasal congestion in seasonal allergic rhinitis: A responder analysis. Allergy Asthma Proc. 2019;40(3):173-9. DOI:10.2500/aap.2019.40.4214
54. Guilbertу TW, Morgan WJ, Zeiger RS, et al. Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma. N Engl J Med. 2006;354(19):1985-97. DOI:10.1056/NEJMoa051378
55. Zeiger RS, Mauger D, Bacharier LB, et al. Daily or Intermittent Budesonide in Preschool Children with Recurrent Wheezing. N Engl J Med. 2011;365(21):1990-2001. DOI:10.1056/NEJMoa1104647
56. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127-35. DOI:10.1016/j.jaci.2008.09.029
57. Hu Y, Zhang J, Wang J. The Efficacy and Safety of Selective H1-Antihistamine versus Leukotriene Receptor Antagonist for Seasonal Allergic Rhinitis: A Meta-Analysis. PLoS ONE. 2014;9(11):e112815. DOI:10.1371/journal.pone.0112815
58. American College of Allergy, Asthma and Immunology (ACAAI). Important COVID-19 Information for those with asthma and/or allergies. 2020. Available at: https://acaai.org/news/important-covid-19-information-those-asthma-andor-allergies. Accessed: 02.08.2020.

________________________________________________

1. Allergic rhinitis. Clinical guidelines. RAACI, NMAO, UPR, 2020 (in Russian)
2. Jeffery PK, Godfrey RWA, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis. 1992;145:890-9.
3. Mandl M, et al. Ann Allergy Asthma Immunol. 1997;79:370-8.
4. Cutler DL, et al. Pediatr Asthma Allergy Immunol. 2006;19:145-53.
5. Haughney J, et al. Respir Med. 2008;102:1681-93.
6. Boulet LP. et al. Chest. 2006;129:661-8.
7. Chalmers GW, et al. Chest. 2001;120:1917-22.
8. Fauler J, et al. Eur J Clin Invest. 1997;27:43-7.
9. Dixon AE. Proc Am Thorac Soc. 2010;7:325-35. 
10. Pratley RE, et al. Obes Res. 1995;3:563-71.
11. Ferrante AW Jr. J Intern Med. 2007;262:408-14. 
12. Shore SA, et al. J Allergy Clin Immunol. 2005;115:103-9. 
13. Shore SA, et al. J Allergy Clin Immunol. 2006;118:389-95.
14. Pinar E, Eryigit O, Oncel S, et al. Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis. Auris Nasus Larynx. 2008;35(1):61-6. DOI:10.1016/j.anl.2007.06.004
15. Berkowitz R, Roberson S, Zora J, et al. Mometasone Furoate Nasal Spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc. 1999;20(3):167-72.
16. Mosges R, Bachert C, Rudack C, et al. Efficacy and safety of Mometasone furoate nasal spray in the treatment of chronic rhinosinusitis. Adv Ther. 2001;28(3):238-49. DOI:10.1007/s12325-010-0105-7
17. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116(6):1289-95. DOI:10.1016/j.jaci.2005.08.044
18. Niti Sardana, et al. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy Asthma Proc. 2010;31:5-9. DOI:10.2500/aap.2010.31.3308
19. HealthStar Communications Inc, in partnership with Schulman Ronca and Bucuvalas Inc. Allergies in America: a landmark survey of nasal allergy sufferers. Executive summary. Florham Park, NJ: Altana Pharma US Inc, 2006.
20. Meltzer E, Blaiss M, Derebery M, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol. 2009;124:43-70. 
21. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758-64.
22. Asher M, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-43.
23. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004;59:1205-10.
24. Lombardi C, Gani F, Landi M, et al. Quantitative assessment of the adherence to sublingual Immunotherapy. J Allergy Clin Immunol. 2004;113:1219-20.
25. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol. 2006;117:946-8.
26. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Otolaryngol Head Neck Surg. 2007;136(Suppl. 6):S107-24. 
27. Köberlein J, Kothe A, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:192-9. 
28. Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med. 2006;100(2):354-62.
29. Bender BG. Motivating patient adherence to allergic rhinitis treatments. Curr Allergy Asthma Rep. 2015;15(3):10. DOI:10.1007/s11882-014-0507-8
30. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol. 2002;88(4):391-4. DOI:10.1016/S1081-1206(10)62370-8
31. Smits W, Inglefield JT, Letz K, et al. Improve immunotherapy with a rapid allergen vaccination schedule: A study of 137 patients. Ear Nose Throat J. 2003;82:881-7.
32. Adamia N, Jorjoliani L, Manjavidze N, et al. Psycho-emotional characteristics of the adolescents with allerrgic rhinitis. Georgian Med News. 2015;243:38-42.
33. He X, Feng Y, Dong YY, et al. Allergic rhinitis and psychological state assessment. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31(5):400-3 (in Chinese).
34. Lebbekh I. Features of the communication of a medical appointment. Cycle “Doctor. How to talk to a patient and influence his adherence“. Publishing solutions licensed Ridero, 2020 (in Russian)
35. Emanuel TJ, Emanuel LL. Four Models of the Physician-Patient Relationship. JAMA. 1992;267(16):2221-6.
36. Ledvanova TYu, Lim VG, Svistunov AA, et al. Communicative competence of a doctor as part of the competence model of training a specialist. Quality management and innovation in education: regional aspect. In 2 vol. Moscow, 2010 (in Russian) 
37. Andriianova EA, Noskova SV. Competence model of a medical university graduate. Pedagogical technologies for the implementation of the competence-based approach in modern medical education. Collection of articles interregion. Scientific-practical conf. Saratov: SSMU, 2009 (in Russian)
38. Tatur IuG. Kompetentnost' v strukture modeli kachestva podgotovki spetsialista. Vysshee obrazovanie segodnia. 2004;3:20-6 (in Russian)
39. Ha JF, Longnecker N. Doctor-patient communication: a review. Ochsner J. 2010;10(1):38-43.
40. Kafetsios K, Anagnostopoulos F, Lempesis E, Valindra A. Doctors’ Emotion Regulation and Patient Satisfaction: A Social-Functional Perspective. Health Commun. 2014;29(2):205-14. DOI:10.1080/10410236.2012.73815 
41. Pirumyan T, Davtyan S. Tolerance as a constructive mechanism of dialogue in the field of Healthcare. Wisdom. 2016;7(2). DOI:10.24234/wisdom.v2i7.136
42. Aruguete MS, Roberts CA. Gender, Affiliation, and Control in Physician–Patient Encounters. Sex Roles. 2000;42:107-18.
43. Deontological Guidelines. Available at: http://www.ceom-ecmo.eu/en/deontological-guidelines-144. Accessed: 02.08.2021.
44. Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat Med. 2012;18(5):726-35. DOI:10.1038/nm.2768
45. Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75(12):3069-76. DOI:10.1111/all.14586
46. Roth-Walter F, Adcock IM, Benito-Villalvilla C, et al. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. Allergy. 2019;74(3):432-48. DOI:10.1111/all.13642
47. Theron AJ, Steel HC, Tintinger GR, et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. Immunol Res. 2014;2014:608930.
48. Cottini M, et al. Asthma phenotypes: the intriguing selective intervention with Montelukast. Asthma Res Pract. 2016;2:11.
49. Kim CK, Callaway Z, Park JS, et al. Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma. Allergy Asthma Immunol Res. 2018;10(6):686-97.
50. Okubo K, Kurono Y, Ichimura K, et al; Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020;69(3):331-45. DOI:10.1016/j.alit.2020.04.001
51. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. 2018.
52. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108-352.
53. Urdaneta E, Tunceli K, Gates D. Effect of mometasone furoate nasal spray on moderate-to-severe nasal congestion in seasonal allergic rhinitis: A responder analysis. Allergy Asthma Proc. 2019;40(3):173-9. DOI:10.2500/aap.2019.40.4214
54. Guilbertу TW, Morgan WJ, Zeiger RS, et al. Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma. N Engl J Med. 2006;354(19):1985-97. DOI:10.1056/NEJMoa051378
55. Zeiger RS, Mauger D, Bacharier LB, et al. Daily or Intermittent Budesonide in Preschool Children with Recurrent Wheezing. N Engl J Med. 2011;365(21):1990-2001. DOI:10.1056/NEJMoa1104647
56. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127-35. DOI:10.1016/j.jaci.2008.09.029
57. Hu Y, Zhang J, Wang J. The Efficacy and Safety of Selective H1-Antihistamine versus Leukotriene Receptor Antagonist for Seasonal Allergic Rhinitis: A Meta-Analysis. PLoS ONE. 2014;9(11):e112815. DOI:10.1371/journal.pone.0112815
58. American College of Allergy, Asthma and Immunology (ACAAI). Important COVID-19 Information for those with asthma and/or allergies. 2020. Available at: https://acaai.org/news/important-covid-19-information-those-asthma-andor-allergies. Accessed: 02.08.2020.